Month: January 2023

Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (“CymaBay” or the “Company”) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the development and commercialization in Japan of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis (“PBC”). Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market seladelpar in Japan for PBC. Kaken will make an upfront payment to CymaBay of ¥4.5 billion (approximately $34.0 million at...

Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of...

– As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy – Petosemtamab clinical update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023 – Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities, expected to fund Merus’ operations into second half 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook. “2023 looks to be another productive year for Merus with multiple value-creating...

– Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – – Among 3 mg/kg VRDN-001 treated patients, 67% were proptosis responders, 56% were overall responders, 67% achieved a Clinical Activity Score (CAS) of 0 or 1, and 20% had complete resolution of their diplopia – – Across all 21 VRDN-001 treated patients to date, 71% were proptosis responders, 67% were overall responders, 62% achieved a CAS of 0 or 1, and 54% had complete resolution of their diplopia, with a favorable safety profile seen across all dose levels – – 3 mg/kg data support planned once-monthly low-volume subcutaneous dosing profile for VRDN-002 and VRDN-003 – WALTHAM, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ:...

Schneider Electric and BitSight announcement.jpg.jpg Schneider Electric and BitSight announcement.jpg.jpgSchneider Electric, the global leader in the digital transformation of energy management and automation, and BitSight, the leader in detecting and managing cyber risk, today announced a strategic partnership to develop a first-of-its-kind global Operational Technology (OT) Risk Identification and Threat Intelligence capability.  In recent years, both opportunistic and advanced cyber threat actors have shown increased willingness to target industrial and operational sites. Schneider Electric and BitSight each see their partnership as an important step in furthering their commitment to improve the security and resilience of their communities​ -​ by detecting OT protocols exposed over the internet and contextualizing them with improved...

VANCOUVER, British Columbia and AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) — Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that has built a technology foundation to deliver revolutionary performance, today announced that it has closed the first tranche of its previously announced non-brokered private placement (the “Financing”) of units (the “Units”) raising approximately 1/3 of the anticipated gross proceeds as previously announced by the Company in its press release dated December 7, 2022 (the “Financing Press Release”). As previously disclosed, each Unit being comprised of (i) an unsecured convertible debenture in a principal amount of C$1,000 and (ii) 52 proportionate voting share purchase warrants. The Company expects to close additional tranches of the Financing...

ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the pricing of a public offering of an aggregate of 2,586,207 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 2,586,207 shares of common stock and Series A-2 warrants to purchase 2,586,207 shares of common stock, at a combined public offering price of $2.90 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The Series A-1 warrants will have an exercise price of $2.65 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-2 warrants...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 06, 2023 (GLOBE NEWSWIRE) — Prospect Park Capital ‎ Corp. ‎‎(CSE:PPK) (the “Company”) is pleased to announce a non-brokered private placement (the “Offering”) of common shares (each, a “Common Share”) and the closing of the first tranche of the Offering. Offering The Company is pleased to announce the Offering of up to 30,000,000 Common Shares at a price of $0.01 per share for total gross proceeds of up to $300,000. The Company intends to use the net proceeds of the Offering for operational, general and administrative purposes. Closing of the Offering is expected to occur in multiple tranches and the Company expects to complete subsequent tranches of the Private Placement on or before February 12,...

VANCOUVER, British Columbia, Jan. 06, 2023 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon” or the “Company”) announces that it has granted 1,055,000 stock options in accordance with the Company’s Equity Incentive Plan (the “Plan”). The Company has granted stock options to certain employees of Rubicon to acquire an aggregate of 1,055,000 common shares at $0.90 per share, for a period of five years. The stock options vest annually in equal tranches over three years. ABOUT RUBICON ORGANICS INC. Rubicon Organics Inc. is the global brand leader in premium organic cannabis products. The Company is vertically integrated through its wholly owned subsidiary Rubicon Holdings Corp, a licensed producer. Rubicon Organics is focused on achieving industry leading profitability through its premium cannabis flower,...

TORONTO, Jan. 06, 2023 (GLOBE NEWSWIRE) — Labrador Uranium Inc. (“LUR”, “Labrador Uranium”, or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) announces that it has granted stock options to purchase an aggregate of 2,650,000 common shares of the Company to management, directors, and consultants of the Company pursuant to the terms of the Company’s share-based incentive plan. The options are exercisable at a price of $0.35 per common share. All Options expire on the date that is five years from the date of grant and vest and become exercisable as to one-third on the date of grant, with the remaining Options vesting in equal parts on the one-year and two-year anniversary of the date of grant. The options are subject to approval of the Canadian Securities Exchange. About Labrador Uranium Inc. Labrador Uranium is engaged in...